z-logo
Premium
Pretreatment with morin ameliorates lipid profiles in isoproterenol‐induced myocardial infarction in wistar rats
Author(s) -
Govindasamy Chandramohan,
Alnumair Khalid S,
Alsaif Mohammed A
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.799.2
Subject(s) - morin , very low density lipoprotein , cholesterol , myocardial infarction , medicine , endocrinology , lipid profile , lipoprotein , blood lipids , chemistry , pathology
Objective Lipids and lipoproteins play an important role in the pathology of myocardial infarction. In the present study evaluated the flavonoid‐morin on lipid profiles in isoproterenol (ISO) induced myocardial infarction in rats. Methods Male albino Wistar rats were pretreated with morin at the optimum dose of 40 mg/kg daily for a period of 30 days. After the treatment period, ISO (85 mg/kg) was subcutaneously injected in rats at an interval of 24 h for 2 days. Results Isoproterenol caused a significant increase in the activity of total, ester, free cholesterol, triglycerides (TG), free fatty acids (FFA) and phospholipids (PL), low density lipoprotein‐cholesterol (LDL‐C) and very low density lipoprotein‐cholesterol (VLDL‐C) in serum and decreased activities in heart phospholipids, serum high density lipoprotein‐cholesterol (HDL‐C) levels. Pretreatment with morin at 40 mg/kg dose blocked these changes to normality which proved their antihyperlipidemic action. Histopathology of heart of ISO administered rat pretreated with morin showed normal myocardium. Conclusion These findings provided evidence that morin was found to be protecting the myocardium against ischemic insult and the protective effect could attribute to its antihyperlipidemic activities. Source: The authors would like to express their gratitude to the National Nutrition Policy Chair, King Saud University, Riyadh, Saudi Arabia for their generous financial support.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here